BackTetraLogic Pharmaceuticals Overview

TetraLogic Pharmaceuticals Total Liabilities

Track TetraLogic Pharmaceuticals's total liabilities ($74M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$73.73M
14.34% YoYΔ $-12.34M vs prior year quarter

Peer trimmed avg / median

Loading

TetraLogic Pharmaceuticals Total Liabilities History

Loading

TetraLogic Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

TetraLogic Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

TetraLogic Pharmaceuticals (TLOG) FAQ

TetraLogic Pharmaceuticals posts a total liabilities of $74M as of September 2016. That compares with $86M in the prior-year period — down 14.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, TetraLogic Pharmaceuticals's total liabilities was $86M. The latest reading is $74M — a 14.3% year-over-year decrease (period ending September 2016). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of TetraLogic Pharmaceuticals's financial statement story. At $74M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TLOG's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; TetraLogic Pharmaceuticals's other metric pages and overview cover the third.

Judging TetraLogic Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $74M here, then scan peer and history charts to see if the gap is persistent.